| Factor Information | |
|---|---|
| Data ID | 464 |
| Factor | Dialysis support(percent) |
| Description | +CHD/ +VAD recipients spent more time on the waiting list (103 days vs 71 days) and were more likely to have worse functional status (60% vs 46%) at transplant and have a clinical infection (29% vs 14%) requiring therapy within 2 weeks before transplant |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | treatment and prognosis |
| Objective | to assess the posttransplant outcomes of pediatric patients with CHD disease who are bridged to cardiac transplantation with VADs. |
| p Value | <0.001 |
| Conclusion | Although more ill pretransplant, CHD patients BTT with a VAD have similar posttransplant survival compared with CHD patients without a VAD and with other non-CHD heart transplant patients. VAD support may mitigate certain risk factors for poor posttransplant outcomes in the challenging CHD cohort. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 29723531 |
| Year | 2018 |
| Title | Transplant Outcomes for Congenital Heart Disease Patients Bridged With a Ventricular Assist Device. |
| Sample | ||
|---|---|---|
| Population | infants/children/adults | |
| Source | Database | |
| Region | Ohio,USA | |
| Method | reviewed | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | CHD+VAD(Treatment) | CHD without VAD(Control) |
| Number | 16(total:143) | 38(total:1728) |
| Age | 10 (2–23) years | 6 (0–20) years |
| Gender (Male: Female) | 96:47 | 1002:726 |
| Marker Level | 0.11 | 0.022 |
